Murtaza Adam, MD
Retina Specialist · Parker, CONPI 1093004806
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $382,712 of the $548,308 with a category attached, or 69.8%. 25 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 24.4% of the total. Among retina specialist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 501 payments — averaging $1094.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$134K
- Astellas Pharma US Inc$133K
- Apellis Pharmaceuticals, Inc.$105K
- Genentech USA, Inc.$87K
- Hoffmann-la Roche Limited$39K
- Novartis$26K
- plus $24K from 19 others
Across 507 payments — averaging $2987.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.3M
- Regeneron$201K
- AbbVie$28K
- F. Hoffmann-la Roche AG$10K
What the payments were for
- Consulting fees$104,98319%
- Speaking & faculty fees$382,71270%
- Travel & lodging$45,4708%
- Food & beverage$15,1423%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 117 | $133,829 |
| Astellas Pharma US Inc | 98 | $133,204 |
| Apellis Pharmaceuticals, Inc. | 72 | $104,803 |
| Genentech USA, Inc. | 93 | $87,052 |
| Hoffmann-la Roche Limited | 14 | $38,734 |
| Novartis | 35 | $26,259 |
| Genentech, Inc. | 6 | $5,570 |
| Dutch Ophthalmic, USA | 7 | $4,343 |
| AbbVie(2 entities) | 26 | $4,263 |
| Neurotech Pharmaceuticals, Inc. | 1 | $3,155 |
| Astellas Pharma Global Development | 2 | $3,132 |
| Eyepoint US, Inc. | 4 | $1,672 |
| Alcon | 4 | $896 |
| Alimera Sciences, Inc. | 4 | $551 |
| Regeneron | 3 | $261 |
| Carl Zeiss Meditec USA, Inc. | 1 | $153 |
| Topcon Healthcare, Inc. | 1 | $104 |
| Biogen | 4 | $75 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Ocular Therapeutix, Inc. | 1 | $50 |
| Harrow Eye, LLC | 2 | $39 |
| Coherus Oncology, Inc. | 2 | $35 |
| Boston Scientific | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$108,983
- EYLEA HD$84,284
- Syfovre$82,775
- VABYSMO$62,077
- EYLEA$48,431
- Lucentis$23,224
- XOLAIR$6,775
- SUSVIMO$6,492
- EVA Ophthalmic Surgical System$3,000
- YUTIQ$2,000
- BEOVU$1,880
- EVA, combined machine$1,131
- TISSUEBLUE$1,131
- OZURDEX$911
- Iluvien$500
- Non-Covered Product$307
- ARTEVO 800$153
- DAILIES$152
- VUITY$106
How this compares
$548,308 in reported general payments places this provider in the 95th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 212 | $7,885 |
| Difluprednate | 44 | $5,195 |
| Prednisolone Acetate | 110 | $4,439 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 253 | $2,979 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 96 | $1,047 |
| Dorzolamide Hcl | 27 | $526 |
| Timolol Maleate | 64 | $422 |
| Latanoprost | 49 | $362 |
| Brimonidine Tartrate | 48 | $285 |
| Triazolam | 29 | $126 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Parker
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Matthew ManryLongmont$43K
- Ashleigh LevisonLafayette$33K
- Mimi LiuEnglewood$23K
- Moss FenbergDurango$20K
- Lynn HassmanAurora$16K
- Adam MartidisColorado Springs$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.